Form 4: Prothena Director Daniel Welch Receives Stock Options

Director Daniel G. Welch was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.

Summary

• Director Daniel G. Welch received a grant of 27,000 stock options on May 15, 2026.
• The options have an exercise price of $9.76 per share.
• The options are set to expire on May 15, 2036.
• Vesting is scheduled for the earlier of the first anniversary of the grant date or the 2027 annual general meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying shares relative to the $9.76 exercise price.

Future Outlook

The options vest in full on the earlier of May 15, 2027, or the date of the 2027 annual general meeting, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to ensure board retention and alignment with corporate performance milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of one-year cliff vesting is a common governance standard to ensure director commitment.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of May 15, 2027, or the 2027 annual general meeting.

Key Dates

Keywords

Prothena, PRTA, Director Compensation, Stock Options, Insider Transaction, Biotech